Trials
Search / Trial NCT00000273

A Laboratory Model for Heroin Abuse Medications - 8

Launched by NEW YORK STATE PSYCHIATRIC INSTITUTE · Sep 20, 1999

Trial Information

Current as of January 20, 2025

Completed

Keywords

Heroin, Opioid Disorders, Substance Related Disorders

ClinConnect Summary

Abuse of prescription opioid medications has increased dramatically in the U.S. during the past decade, as indicated by a variety of epidemiological sources. However, few studies have systematically examined the relative reinforcing effects of commonly abused opioid medications. The current inpatient study was designed to compare the effects of intravenously delivered fentanyl , oxycodone, morphine, buprenorphine and heroin in morphine-maintained heroin abusers. All of the participants received all of the drugs tested; drugs and doses were administered in non-systematic order.

Gender

ALL

Eligibility criteria

  • Inclusion Criterion
  • 1. DSM IV criteria for opioid dependence
  • 2. No major mood, psychotic, or anxiety disorder
  • 3. Physically healthy
  • 4. Able to perform study procedures
  • 5. 21-45 years of age
  • 6. Current use of i.v. heroin in amounts/frequencies
  • 7. Not seeking treatment for opioid dependence
  • Exclusion Criterion
  • 1. DSM IV criteria for dependence on drugs other
  • 2. Participants requesting treatment
  • 3. Participants on parole or probation
  • 4. Pregnancy or lactation
  • 5. Birth, miscarriage or abortion with 6 months
  • 6. Recent history of or current significant violent behavior
  • 7. Current major Axis I psychopathology, other than heroin dependence ( e.g., mood disorder with functional impairment or suicide risk, schizophrenia), which might interfere with ability to participate in the study
  • 8. Hepatitis with SGOT or SGPT \> 3 times normal
  • 9. Significant suicide risk
  • 10. Current or history of chronic pain
  • 11. Sensitivity, allergy, or contraindication to opioids

Trial Officials

Herbert Kleber, M.D.

Principal Investigator

New York State Psychiatric Institute

About New York State Psychiatric Institute

The New York State Psychiatric Institute (NYSPI) is a leading research organization dedicated to advancing the understanding and treatment of mental health disorders. Affiliated with Columbia University, NYSPI integrates clinical research with cutting-edge scientific inquiry to develop innovative therapeutic strategies and improve patient care. With a focus on a wide range of psychiatric conditions, NYSPI conducts clinical trials that aim to translate findings from laboratory research into effective interventions, enhancing the quality of life for individuals affected by mental illness. Committed to ethical research practices and collaboration, NYSPI plays a pivotal role in shaping the future of psychiatric care through rigorous scientific exploration and community engagement.

Locations

New York, New York, United States

New York, New York, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials